Pharma Mar, S.A. (PHM.MC)
EUR 76.95
(0.59%)
EUR 76.95
(0.59%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.82 Million EUR | -112.14% |
| 2022 | 44.07 Million EUR | -52.33% |
| 2021 | 92.44 Million EUR | -40.72% |
| 2020 | 155.94 Million EUR | 992.38% |
| 2019 | -17.47 Million EUR | -24.18% |
| 2018 | -14.07 Million EUR | 20.41% |
| 2017 | -17.68 Million EUR | 5.48% |
| 2016 | -18.7 Million EUR | -265.12% |
| 2015 | 11.32 Million EUR | -44.02% |
| 2014 | 20.23 Million EUR | 6.76% |
| 2013 | 18.95 Million EUR | 30.13% |
| 2012 | 14.56 Million EUR | 106.16% |
| 2011 | 7.06 Million EUR | 174.25% |
| 2010 | -9.51 Million EUR | 70.51% |
| 2009 | -32.27 Million EUR | 12.91% |
| 2008 | -37.05 Million EUR | 18.26% |
| 2007 | -45.33 Million EUR | 5.59% |
| 2006 | -48.01 Million EUR | -471.78% |
| 2005 | -8.39 Million EUR | 3.49% |
| 2004 | -8.7 Million EUR | 68.63% |
| 2003 | -27.73 Million EUR | 37.39% |
| 2002 | -44.3 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -730 Thousand EUR | 83.02% |
| 2024 Q1 | -4.29 Million EUR | 16.94% |
| 2024 Q3 | 5.48 Million EUR | 850.82% |
| 2023 FY | -5.35 Million EUR | -112.14% |
| 2023 Q1 | -2.65 Million EUR | -140.18% |
| 2023 Q2 | 4.04 Million EUR | 252.6% |
| 2023 Q3 | -184 Thousand EUR | -104.55% |
| 2023 Q4 | -5.17 Million EUR | -2713.04% |
| 2022 FY | 44.07 Million EUR | -52.33% |
| 2022 Q1 | 19.01 Million EUR | -56.15% |
| 2022 Q3 | 11.85 Million EUR | 58.02% |
| 2022 Q2 | 7.5 Million EUR | -60.54% |
| 2022 Q4 | 6.6 Million EUR | -44.32% |
| 2021 Q3 | 49.04 Million EUR | 371.46% |
| 2021 FY | 92.44 Million EUR | -40.72% |
| 2021 Q1 | 18.1 Million EUR | -3.21% |
| 2021 Q2 | -18.06 Million EUR | -199.79% |
| 2021 Q4 | 43.36 Million EUR | -11.59% |
| 2020 Q2 | 44.52 Million EUR | -36.84% |
| 2020 FY | 155.94 Million EUR | 992.38% |
| 2020 Q4 | 18.7 Million EUR | -15.79% |
| 2020 Q1 | 70.5 Million EUR | 296.73% |
| 2020 Q3 | 22.21 Million EUR | -50.11% |
| 2019 Q2 | -4.55 Million EUR | 50.02% |
| 2019 Q4 | -35.83 Million EUR | -211.89% |
| 2019 Q1 | -9.11 Million EUR | 15.02% |
| 2019 FY | -17.47 Million EUR | -24.18% |
| 2019 Q3 | 32.02 Million EUR | 802.65% |
| 2018 Q3 | -6.63 Million EUR | -209.85% |
| 2018 Q4 | -10.73 Million EUR | -61.78% |
| 2018 FY | -14.07 Million EUR | 20.41% |
| 2018 Q1 | -2.74 Million EUR | 63.99% |
| 2018 Q2 | 6.03 Million EUR | 319.88% |
| 2017 Q1 | -1.65 Million EUR | 78.08% |
| 2017 Q4 | -7.62 Million EUR | -33.79% |
| 2017 Q3 | -5.7 Million EUR | -110.88% |
| 2017 FY | -17.68 Million EUR | 5.48% |
| 2017 Q2 | -2.7 Million EUR | -63.62% |
| 2016 Q4 | -7.53 Million EUR | -291.53% |
| 2016 FY | -18.7 Million EUR | -265.12% |
| 2016 Q3 | -1.92 Million EUR | 44.87% |
| 2016 Q2 | -3.49 Million EUR | 39.29% |
| 2016 Q1 | -5.75 Million EUR | -1806.82% |
| 2015 FY | 11.32 Million EUR | -44.02% |
| 2015 Q3 | 4.59 Million EUR | 393.04% |
| 2015 Q1 | 7.96 Million EUR | 670.7% |
| 2015 Q2 | -1.56 Million EUR | -119.67% |
| 2015 Q4 | 337 Thousand EUR | -92.66% |
| 2014 Q4 | -1.39 Million EUR | -165.11% |
| 2014 Q2 | 1.41 Million EUR | -92.2% |
| 2014 Q1 | 18.07 Million EUR | 2639.24% |
| 2014 FY | 20.23 Million EUR | 6.76% |
| 2014 Q3 | 2.14 Million EUR | 52.06% |
| 2013 Q2 | 931 Thousand EUR | -94.34% |
| 2013 Q1 | 16.45 Million EUR | 580.5% |
| 2013 FY | 18.95 Million EUR | 30.13% |
| 2013 Q4 | 660 Thousand EUR | -27.31% |
| 2013 Q3 | 908 Thousand EUR | -2.47% |
| 2012 Q2 | 17.89 Million EUR | 463.05% |
| 2012 Q4 | -3.42 Million EUR | -32.19% |
| 2012 FY | 14.56 Million EUR | 106.16% |
| 2012 Q1 | -4.92 Million EUR | -126.09% |
| 2012 Q3 | -2.59 Million EUR | -114.48% |
| 2011 Q1 | -3.67 Million EUR | 53.82% |
| 2011 Q4 | 18.89 Million EUR | 592.83% |
| 2011 FY | 7.06 Million EUR | 174.25% |
| 2011 Q3 | -3.83 Million EUR | -17322.73% |
| 2011 Q2 | -22 Thousand EUR | 99.4% |
| 2010 FY | -9.51 Million EUR | 70.51% |
| 2010 Q3 | -974 Thousand EUR | -289.49% |
| 2010 Q2 | 514 Thousand EUR | 147.16% |
| 2010 Q1 | -1.09 Million EUR | 94.98% |
| 2010 Q4 | -7.96 Million EUR | -717.97% |
| 2009 Q2 | -1.92 Million EUR | 20.3% |
| 2009 Q3 | -6.21 Million EUR | -222.1% |
| 2009 Q4 | -21.71 Million EUR | -249.66% |
| 2009 FY | -32.27 Million EUR | 12.91% |
| 2009 Q1 | -2.41 Million EUR | 78.55% |
| 2008 Q1 | -11.49 Million EUR | 0.0% |
| 2008 Q3 | -12.54 Million EUR | -624.54% |
| 2008 FY | -37.05 Million EUR | 18.26% |
| 2008 Q4 | -11.27 Million EUR | 10.14% |
| 2008 Q2 | -1.73 Million EUR | 84.94% |
| 2007 FY | -45.33 Million EUR | 5.59% |
| 2006 FY | -48.01 Million EUR | -471.78% |
| 2005 FY | -8.39 Million EUR | 3.49% |
| 2004 FY | -8.7 Million EUR | 68.63% |
| 2003 FY | -27.73 Million EUR | 37.39% |
| 2002 FY | -44.3 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Atrys Health, S.A. | -1.58 Million EUR | -141.909% |
| Biotechnologies Assets SA | 2.65 Million EUR | 244.196% |
| Laboratorios Farmaceuticos Rovi, S.A. | 220.25 Million EUR | 101.738% |